http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-153871-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a2c7072432beb3242a97a2c0f31f803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ea4440eb72b01216fb4c86a0b66b11c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739
filingDate 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d138767b8c79a1950eda5099902eef0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aa17a4b73b787e16e2cc977551f7f9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ee11d27ef3e21fa24463358769ae2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3f2cbd4d5a2e708e0dd6f7e16f57673
publicationDate 2009-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-153871-A1
titleOfInvention Compositions and methods for treating neurological disorders
abstract Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a neurodegenerative autoimmune disorder such as Multiple Sclerosis are contemplated utilizing proteosomes and/or Glatiramer Acetate, wherein the GA is in a submicron emulsion or a nanoemulsion.
priorityDate 2004-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448746680
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081884

Total number of triples: 28.